ANGIOTECH ANNOUNCES POSITIVE INTERIM SAFETY DATA WITH VASCULAR WRAP AT ONE YEAR

Angiotech Pharmaceuticals recently announced positive interim 12-month safety results from its novel and proprietary Vascular Wrap paclitaxel-eluting mesh trial presented at the VEITHsymposium in New York. This European first-in-man pilot study is designed to evaluate the safety of a novel and proprietary drug-loaded Vascular Wrap in the prevention of stenosis after peripheral bypass surgery.
Biotech Intelligence